OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B
Gi‐Ae Kim, Young‐Suk Lim, Seungbong Han, et al.
Gut (2017) Vol. 67, Iss. 5, pp. 945-952
Closed Access | Times Cited: 228
Gi‐Ae Kim, Young‐Suk Lim, Seungbong Han, et al.
Gut (2017) Vol. 67, Iss. 5, pp. 945-952
Closed Access | Times Cited: 228
Showing 1-25 of 228 citing articles:
Chronic hepatitis B virus infection
Wai‐Kay Seto, Ying-Ru Lo, Jean‐Michel Pawlotsky, et al.
The Lancet (2018) Vol. 392, Iss. 10161, pp. 2313-2324
Closed Access | Times Cited: 467
Wai‐Kay Seto, Ying-Ru Lo, Jean‐Michel Pawlotsky, et al.
The Lancet (2018) Vol. 392, Iss. 10161, pp. 2313-2324
Closed Access | Times Cited: 467
Hepatitis B
Wen‐Juei Jeng, George Papatheodoridis, Anna S. Lok
The Lancet (2023) Vol. 401, Iss. 10381, pp. 1039-1052
Closed Access | Times Cited: 289
Wen‐Juei Jeng, George Papatheodoridis, Anna S. Lok
The Lancet (2023) Vol. 401, Iss. 10381, pp. 1039-1052
Closed Access | Times Cited: 289
HBV-Induced Immune Imbalance in the Development of HCC
Yongyan Chen, Zhigang Tian
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 212
Yongyan Chen, Zhigang Tian
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 212
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology (2019) Vol. 25, Iss. 2, pp. 93-159
Open Access | Times Cited: 191
Clinical and Molecular Hepatology (2019) Vol. 25, Iss. 2, pp. 93-159
Open Access | Times Cited: 191
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 2, pp. 276-331
Open Access | Times Cited: 89
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 2, pp. 276-331
Open Access | Times Cited: 89
Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients
Won‐Mook Choi, Terry Cheuk‐Fung Yip, W. Ray Kim, et al.
Hepatology (2024) Vol. 80, Iss. 2, pp. 428-439
Open Access | Times Cited: 22
Won‐Mook Choi, Terry Cheuk‐Fung Yip, W. Ray Kim, et al.
Hepatology (2024) Vol. 80, Iss. 2, pp. 428-439
Open Access | Times Cited: 22
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial
Young‐Suk Lim, Ming‐Lung Yu, Jonggi Choi, et al.
The Lancet. Gastroenterology & hepatology (2025)
Closed Access | Times Cited: 2
Young‐Suk Lim, Ming‐Lung Yu, Jonggi Choi, et al.
The Lancet. Gastroenterology & hepatology (2025)
Closed Access | Times Cited: 2
HBV induced hepatocellular carcinoma and related potential immunotherapy
Liyang Jia, Yanan Gao, Yaowu He, et al.
Pharmacological Research (2020) Vol. 159, pp. 104992-104992
Closed Access | Times Cited: 98
Liyang Jia, Yanan Gao, Yaowu He, et al.
Pharmacological Research (2020) Vol. 159, pp. 104992-104992
Closed Access | Times Cited: 98
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, et al.
Clinical and Molecular Hepatology (2020) Vol. 26, Iss. 4, pp. 411-429
Open Access | Times Cited: 85
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, et al.
Clinical and Molecular Hepatology (2020) Vol. 26, Iss. 4, pp. 411-429
Open Access | Times Cited: 85
Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients
Gi‐Ae Kim, Seungbong Han, Gwang Hyeon Choi, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 51, Iss. 11, pp. 1169-1179
Closed Access | Times Cited: 76
Gi‐Ae Kim, Seungbong Han, Gwang Hyeon Choi, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 51, Iss. 11, pp. 1169-1179
Closed Access | Times Cited: 76
Risk of Hematologic Malignant Neoplasms From Abdominopelvic Computed Tomographic Radiation in Patients Who Underwent Appendectomy
Kyung Hee Lee, Seungjae Lee, Ji Hoon Park, et al.
JAMA Surgery (2021) Vol. 156, Iss. 4, pp. 343-343
Open Access | Times Cited: 70
Kyung Hee Lee, Seungjae Lee, Ji Hoon Park, et al.
JAMA Surgery (2021) Vol. 156, Iss. 4, pp. 343-343
Open Access | Times Cited: 70
Pathway to global elimination of hepatitis B: HBV cure is just the first step
Jessica Howell, Chris Seaman, Jack Wallace, et al.
Hepatology (2023) Vol. 78, Iss. 3, pp. 976-990
Open Access | Times Cited: 24
Jessica Howell, Chris Seaman, Jack Wallace, et al.
Hepatology (2023) Vol. 78, Iss. 3, pp. 976-990
Open Access | Times Cited: 24
Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B
Young‐Suk Lim, W. Ray Kim, Douglas T. Dieterich, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 997-997
Open Access | Times Cited: 23
Young‐Suk Lim, W. Ray Kim, Douglas T. Dieterich, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 997-997
Open Access | Times Cited: 23
Noninvasive diagnosis model for predicting significant liver inflammation in patients with chronic hepatitis B in the immune-tolerant phase
Shanshan Chen, Lu Huang, Yong S. Chu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Shanshan Chen, Lu Huang, Yong S. Chu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States
Kevin Pak, Ryan Sachar, Sammy Saab
Digestive Diseases and Sciences (2025)
Closed Access | Times Cited: 1
Kevin Pak, Ryan Sachar, Sammy Saab
Digestive Diseases and Sciences (2025)
Closed Access | Times Cited: 1
Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load
Noam Peleg, Assaf Issachar, Orly Sneh Arbib, et al.
JHEP Reports (2019) Vol. 1, Iss. 1, pp. 9-16
Open Access | Times Cited: 68
Noam Peleg, Assaf Issachar, Orly Sneh Arbib, et al.
JHEP Reports (2019) Vol. 1, Iss. 1, pp. 9-16
Open Access | Times Cited: 68
Should Treatment Indications for Chronic Hepatitis B Be Expanded?
Wen‐Juei Jeng, Anna S. Lok
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 10, pp. 2006-2014
Open Access | Times Cited: 60
Wen‐Juei Jeng, Anna S. Lok
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 10, pp. 2006-2014
Open Access | Times Cited: 60
The epidemiology of hepatitis B virus infection in Korea
Sun Young Yim, Ji Hoon Kim
The Korean Journal of Internal Medicine (2019) Vol. 34, Iss. 5, pp. 945-953
Open Access | Times Cited: 59
Sun Young Yim, Ji Hoon Kim
The Korean Journal of Internal Medicine (2019) Vol. 34, Iss. 5, pp. 945-953
Open Access | Times Cited: 59
Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival
Shukui Qin, Qing Li, Jian Xu, et al.
Cancer Science (2020) Vol. 111, Iss. 11, pp. 4218-4231
Open Access | Times Cited: 58
Shukui Qin, Qing Li, Jian Xu, et al.
Cancer Science (2020) Vol. 111, Iss. 11, pp. 4218-4231
Open Access | Times Cited: 58
Application of Raman spectroscopy in the detection of hepatitis B virus infection
Dongni Tong, Cheng Chen, Jingjing Zhang, et al.
Photodiagnosis and Photodynamic Therapy (2019) Vol. 28, pp. 248-252
Closed Access | Times Cited: 57
Dongni Tong, Cheng Chen, Jingjing Zhang, et al.
Photodiagnosis and Photodynamic Therapy (2019) Vol. 28, pp. 248-252
Closed Access | Times Cited: 57
Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune‐tolerant phase
Han Ah Lee, Hyun Woong Lee, In Hee Kim, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 52, Iss. 1, pp. 196-204
Closed Access | Times Cited: 57
Han Ah Lee, Hyun Woong Lee, In Hee Kim, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 52, Iss. 1, pp. 196-204
Closed Access | Times Cited: 57
East Asia expert opinion on treatment initiation for chronic hepatitis B
Jia‐Horng Kao, Tsung‐Hui Hu, Jidong Jia, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 52, Iss. 10, pp. 1540-1550
Closed Access | Times Cited: 56
Jia‐Horng Kao, Tsung‐Hui Hu, Jidong Jia, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 52, Iss. 10, pp. 1540-1550
Closed Access | Times Cited: 56
Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis
Jia‐Cheng Liu, Jian Wang, Xiaomin Yan, et al.
Hepatology Communications (2021) Vol. 6, Iss. 4, pp. 855-866
Open Access | Times Cited: 54
Jia‐Cheng Liu, Jian Wang, Xiaomin Yan, et al.
Hepatology Communications (2021) Vol. 6, Iss. 4, pp. 855-866
Open Access | Times Cited: 54
Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update
Paul Martin, Mindie H. Nguyen, Douglas T. Dieterich, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 8, pp. 1766-1775
Open Access | Times Cited: 50
Paul Martin, Mindie H. Nguyen, Douglas T. Dieterich, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 8, pp. 1766-1775
Open Access | Times Cited: 50
Viral hepatitis: Milestones, unresolved issues, and future goals
Pietro Torre, Andrea Aglitti, Mario Masarone, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 28, pp. 4603-4638
Open Access | Times Cited: 42
Pietro Torre, Andrea Aglitti, Mario Masarone, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 28, pp. 4603-4638
Open Access | Times Cited: 42
